UK Life Sciences Company Directory

TCR bispecific immunotherapies for cancer and infectious disease

Immunocore is a commercial-stage biopharma developing T cell receptor bispecific immunotherapies. Its lead product tebentafusp received FDA approval in 2022 for metastatic uveal melanoma and generated $400 million in revenue in 2025. Three Phase 3 trials are enrolling across melanoma indications, with topline data…

Bispecific TCR therapies targeting HLA-Class II cancer antigens

Yellowstone Biosciences is a pre-clinical biotechnology company developing bispecific T-cell receptor therapies for oncology. The company targets a novel class of HLA Class II antigens expressed across multiple cancers, with an initial programme focused on acute myeloid leukaemia. Its approach is designed to…

TSG-6 protein therapeutics for inflammatory and degenerative disease

Link Biologics is a preclinical-stage biotechnology company developing protein therapeutics based on TSG-6, an endogenous human protein with anti-inflammatory and tissue-protective properties. Spun out from the University of Manchester in 2021, the company is advancing its lead asset, Link_TSG6, across programmes in…

Neuroactive therapeutics through genetic engineering of fungi and plants

Empyrean Neuroscience is a biopharma company that uses genetic engineering of fungi and plants to develop small molecule therapeutics for neuropsychiatric and neurologic disorders. Using CRISPR/Cas9 and proprietary transformation technologies, the platform enables precise modulation of neuroactive compound production.…

Antibody immunotherapy targeting toxic tau for neurodegenerative disease

TauC3 Biologics is a preclinical biopharmaceutical company developing an antibody-based immunotherapy that targets tauC3, a toxic, truncated form of the tau protein implicated in neurodegenerative disease. Its lead candidate, TBL-100, is a humanized monoclonal antibody developed with LifeArc, designed to selectively…

Antibody therapeutics targeting glycosphingolipid inflammation

Protalea Bio is a biotech company developing first-in-class therapeutic antibodies to prevent progression from precancerous states to active blood cancers including multiple myeloma and B-cell lymphoma. The company's approach targets glycosphingolipid-related inflammation before disease onset, building on over fifteen…

Structure-guided small-molecule therapeutics for antiviral and metabolic diseases

Halo Therapeutics is a University of Bristol spinout developing structure-guided small-molecule medicines for infectious and metabolic diseases. Its research combines cryo-electron microscopy, protein biophysics and computational chemistry to identify drug-binding pockets and design selective compounds. Its antiviral…

G-quadruplex-targeting medicines for precision cancer treatment

Genome Therapeutics is a biotechnology company developing cancer medicines that target G-quadruplex DNA structures associated with tumour biology. Its approach builds on research into non-canonical DNA folding and how these structures influence gene regulation and cancer cell vulnerabilities. The company develops…

Clinical-stage peptide therapeutics for autoimmune and infectious disease

ImmuPharma is a clinical-stage biopharmaceutical company developing peptide-based therapeutics and precision diagnostics for autoimmune disease, infectious disease and metabolic disorders. Its lead candidate, a first-in-class immunormalizer for lupus, has completed a Phase III pivotal trial, aiming to restore normal…

RNAi therapeutics for Parkinson's and neurodegenerative diseases

Valaya Bio is developing RNA interference (RNAi) therapeutics for age-related neurodegenerative diseases, initially Parkinson's disease. Its platform uses precision oligonucleotides designed to modulate upstream molecular regulators implicated in multiple disease pathways, including mitochondrial dysfunction,…

Bacterial-like particle vaccine platform targeting recurrent UTIs

Spectre Bio is a biotechnology company developing a non-antibiotic prophylactic vaccine for recurrent UTIs, a major unmet medical need and significant driver of antimicrobial resistance. The company's platform produces programmable, non-replicative bacterial cells that retain a full native antigen profile while being…

Biparatopic PD-1/VEGFR2 antibody for solid tumour oncology

Ottimo Pharma is a clinical-stage biotechnology company developing biparatopic antibody therapeutics for solid tumour cancers. Its lead programme, Jankistomig, is a first-in-class single-agent IgG antibody that simultaneously targets PD-1 for immune checkpoint inhibition and VEGFR2 to suppress tumour angiogenesis. The…

Small molecule therapeutics targeting astrocytes in Parkinson's disease

Cellestial Health is a pre-clinical stage biotechnology company and University of Cambridge spinout developing small molecule therapeutics for Parkinson's disease and other neurodegenerative conditions. The company's approach targets astrocytic networks, a class of brain cells whose dysregulation contributes to…

Nanotechnology drug delivery platform for precision medicines

Nanomerics is a UK speciality pharmaceutical company developing precision medicines using its proprietary technology, a polymer nanotechnology platform that improves the bioavailability and targeting of water-insoluble drugs and peptides. The technology enables delivery via nasal, ocular, oral, and blood-brain barrier…

Clinical-stage company developing treatments for cancer cachexia and muscle wasting

Actimed Therapeutics is a clinical-stage specialty pharma developing treatments for cancer cachexia and muscle wasting disorders, areas with significant unmet need and no globally approved therapies. Its lead programme has completed Phase 1 and received FDA IND approval, with a Phase 2b/3 trial planned in non-small…

Precision cancer vaccines to prevent metastatic recurrence

Infinitopes is a clinical-stage biotechnology company developing therapeutic cancer vaccines designed to prevent metastatic recurrence. Its lead candidate ITOP1 is a precision viral vector cancer vaccine targeting tumour antigens in patients with surgically resectable oesophageal adenocarcinoma, to be administered in…

Genomics platform developing RNA therapies for chronic liver disease

Ochre Bio is a biotechnology company developing RNA therapeutics for chronic liver disease using a platform built on large-scale human liver datasets. The platform integrates gene perturbation atlases, single-cell genomics from perfused donor livers, and machine learning to identify and validate disease-modifying drug…

ML-driven antibody discovery platform for solid tumour therapeutics

LabGenius Therapeutics is a company developing next-generation therapeutic antibodies using its closed-loop machine learning platform. The platform integrates AI, robotic automation and high-throughput experimentation to co-optimise multispecific antibodies across potency, selectivity and manufacturability…

Global biopharma with UK R&D hub in Hertfordshire

Roche Products is the UK pharmaceutical arm of F. Hoffmann-La Roche, headquartered at Welwyn Garden City in Hertfordshire. The site employs over 1,900 people and serves as a primary hub for early-stage drug discovery, clinical development, computational sciences, and commercial operations. The UK operation contributes…

Global commercialisation of specialty, hospital and rare disease medicines

ADVANZ PHARMA is a global pharmaceutical company focused on the commercialisation of specialty, hospital and rare disease medicines, partnering with biopharma and pharmaceutical development companies to bring treatments to patients. The company's portfolio spans therapeutic areas including hepatology,…